LakeShore Biopharma (LSB) Price-to-Projected Revenue Ratio

How does the PRC's state procurement system impact the position of LakeShore Biopharma Co. (LSB)? LakeShore Biopharma Co. (LSB) maintains its leadership through unique cell-free synthesis, which ensures high vaccine purity and pricing power. Revenues are based on government orders and immunization schedules, creating moderate stability in cash flows. The forward P/S ratio smooths out the noise during the post-crisis recovery, while the 1.30 mark reflects the current state of fundamental expectations.

LSB LakeShore Biopharma: Market Cap to Projected Revenue in the range 10/06/2024 - 10/07/2024

YS Biopharma Co., Ltd. (LSB) - metric breakdowns and financial figures

- current price and projected stock value:

Stock Price LakeShore Biopharma|LSB - Analyst Median Target

- market capitalization details:

Market Value LSB|LSB - Total Enterprise Value

- book value of equity indicators:

Net Assets per Single Share LakeShore Biopharma|LSB - Accounting Capitalization|Market Value to Book Value Ratio ysbiopharm.com|LSB - Company Total Asset Base

- debt and liquidity data:

- business earnings and investment ratios data:

LSB - Net Financial Result|Projected Future Earnings LakeShore Biopharma Co.|LSB - Company Value to Net Income|Future Price to Earnings YS Biopharma|LSB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSB|LSB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) LakeShore Biopharma|LSB - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ysbiopharm.com|LSB - Earnings per share increase in current year|Earnings growth forecast for next year LakeShore Biopharma Co.

- sales and revenue indicators:

LSB - Company Revenue|Projected Sales Volume LakeShore Biopharma|LSB - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio LSB

Fundamental company analysis:LSB (LakeShore Biopharma)

Original product of YS Biopharma Co., Ltd.

Analyzing LakeShore Biopharma Co. (LSB) through the company's forward P/S ratio allows for an assessment of the business's market value relative to expected sales volume. This multiple compares current market capitalization with future revenue, reflecting investment expectations regarding vaccine demand in China and the success of new biopharmaceutical developments. Sharp fluctuations in this indicator signal a shift in the market's valuation of the company's potential in the production of anti-infective drugs.

Competitors of LakeShore Biopharma Co.

Forward P/S Multiple SMMT (Summit Therapeutics Inc.)|Market Cap to Expected Sales Ratio Moderna Inc (MRNA)|PCVX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tarsus Corp|CorMedix Inc. (CRMD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MCRB|Price-to-Projected Revenue Ratio Spero Therapeutics, Inc.|Scynexis (SCYX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio AN2 Therapeutics, Inc. (ANTX)|Price-to-Projected Revenue Ratio PYPD (polypid.com)|Forward P/S Multiple ITRM (Iterum Therapeutics)|Forward P/S Multiple BiomX Inc PHGE|SNGX - Price-to-Projected Revenue Ratio|SXTP - Forward P/S Multiple|OGEN: Forward P/S Multiple|Market Cap to Future Revenue Ratio OpGen Corporation (OPGN)